Literature DB >> 32738818

Conditional relative survival and competing mortality in patients who underwent surgery for lung cancer: A nationwide cohort study.

Jung Eun Yoo1, Kyungdo Han2, Dong Wook Shin3,4,5, Sang Hyun Park6, In Young Cho7, Dong Woog Yoon8, Jongho Cho9, Kyu-Won Jung10.   

Abstract

We aimed to investigate the conditional relative survival (CRS) and competing mortality in patients who underwent surgery for newly diagnosed lung cancer. Using a nationwide population-based database, we calculated 5-year CRS on 1 to 5 years survival after surgery. These rates were reported according to age, sex, socioeconomic status, comorbidities and treatment received. We also estimated cause-specific mortality with the consideration of competing risk. We identified 34 349 patients newly diagnosed with primary lung cancer from 2007 to 2013. The 5-year CRS after surgery was 71.7% at baseline improving steadily to 85.4% by 5 years, suggesting evidence of persistent excess mortality risk. Throughout the period, lung cancer was the most common cause of death, contributing to 83.6% mortality 1 year after surgery and 66.3% 5 years after surgery. Other causes of death included cardiovascular disease and respiratory disease, which increased continuously with time after surgery. CRS rates for patients with lung cancer improved over time but did not reach the level of the general population even 5 years after surgery. Although the main cause of death continues to be lung cancer, death from noncancer causes increased with time after surgery. Evidence-based decisions could be made on the dynamic risk profiles of the patients.
© 2020 Union for International Cancer Control.

Entities:  

Keywords:  cancer survivorship; cause of death; competing mortality; conditional relative survival; lung cancer

Mesh:

Year:  2020        PMID: 32738818     DOI: 10.1002/ijc.33239

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Causes of death and conditional survival estimates of long-term lung cancer survivors.

Authors:  Qun Zhang; Yuan Dai; Hongda Liu; Wenkui Sun; Yuming Huang; Zheng Gong; Shanlin Dai; Hui Kong; Weiping Xie
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

2.  Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival.

Authors:  Dong Wook Shin; Jong Ho Cho; Jung Eun Yoo; Juhee Cho; Dong Woog Yoon; Genehee Lee; Sumin Shin; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Jae Ill Zo; Young Mog Shim
Journal:  Cancer Res Treat       Date:  2021-03-09       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.